The second part of this is the fact that within the first couple of days, youre looking at almost half the people are going to get some kind of gastrointestinal side effects, nausea, vomiting, diarrhea, constipation
Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained
Others suggest that daily oral B12 supplementation provides more consistent levels and avoids the risks of combining it with the peptide altogether
Cloudiness or particulate formation indicates peptide aggregation, bacterial contamination, or chemical degradationnone of which are reversible
Does Lactobacillus reuteri influence ergothioneine levels in the human body